Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65)

Journal of General Virology

Volumn 87, Issue 4, 2006, Pages 777-787

  Yue, Yujuan ^a   Kaur, Amitinder ^b   Zhou, Shan Shan ^a   Barry, Peter A ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; GANCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE LOCATION; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; LONGITUDINAL STUDY; NONHUMAN; OPEN READING FRAME; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RHESUS MONKEY; SEQUENCE HOMOLOGY; VACCINATION; VIRION; VIRUS GENE; VIRUS PATHOGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON TYPE II; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 8; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MACACA MULATTA;

EID: 33645546296     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81516-0     Document Type: Article

References (63)

1. Alford, C. A. & Britt, W. J. (1993). Cytomegalovirus. In The Human Herpesviruses, pp. 227-255. Edited by B. Roizman, R. J. Whitley & C. Lopez. New York: Raven Press.
2. Arcangeletti, M. C., De Conto, F., Ferraglia, F. & 11 other authors (2003). Human cytomegalovirus proteins PP65 and IEP72 are targeted to distinct compartments in nuclei and nuclear matrices of infected human embryo fibroblasts. J Cell Biochem 90, 1056-1067.
3. Barry, P. A. & Chang, W.-L. W. (2005). Primate betaherpesviruses. In Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Edited by A. Arvin, G. Campadielli-Fiume, P. S. Moore, E. Mocarski, B. Roizman, R. Whitley & K. Yamanishi. Cambridge: Cambridge University Press.
4. Beninga, J., Kropff, B. & Mach, M. (1995). Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 76, 153-160.
5. Berencsi, K., Gyulai, Z., Gönczöl, E. & 9 other authors (2001). A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183, 1171-1179.
6. Boppana, S. B. & Britt, W. J. (1995). Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171, 1115-1121.
7. Boppana, S. B. & Britt, W. J. (1996). Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222, 293-296.
8. Bunde, T., Kirchner, A., Hoffmeister, B. & 8 other authors (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201, 1031-1036.
9. Campbell, A. L. & Herold, B. C. (2004). Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients. Pediatr Transplant 8, 619-627.
10. Chang, W. L. W., Kirchoff, V., Pari, G. S. & Barry, P. A. (2002). Replication of rhesus cytomegalovirus in life-expanded rhesus fibroblasts expressing human telomerase. J Virol Methods 104, 135-146.
11. Chee, M. S., Bankier, A. T., Beck, S. & 12 other authors (1990). Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154, 125-169.
12. Del Val, M., Schlicht, H.-J., Volkmer, H., Messerle, M., Reddehase, M. J. & Koszinowski, U. H. (1991). Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65, 3641-3646.
13. Depto, A. S. & Stenberg, R. M. (1989). Regulated expression of the human cytomegalovirus pp65 gene: octamer sequence in the promoter is required for activation by viral gene products. J Virol 63, 1232-1238.
14. Dolan, A., Cunningham, C., Hector, R. D. & 12 other authors (2004). Genetic content of wild-type human cytomegalovirus. J Gen Virol 85, 1301-1312.
15. DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P.-M., Miller, J. H. & Calos, M. P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7, 379-387.
16. +-T-cell responses to human cytomegalovirus reveals broad and multi-specific reactivities in healthy virus carriers. J Virol 77, 5226-5240.
17. Fowler, K. B., Stagno, S., Pass, R. F., Britt, W. J., Boll, T. J. & Alford, C. A. (1992). The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326, 663-667.
18. Gallina, A., Percivalle, E., Simoncini, L., Revello, M. G., Gerna, G. & Milanesi, G. (1996). Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 77, 1151-1157.
19. Geballe, A. P., Leach, F. S. & Mocarski, E. S. (1986). Regulation of cytomegalovirus late gene expression: γ genes are controlled by posttranscriptional events. J Virol 57, 864-874.
20. Gonczol, E. & Plotkin, S. (2001). Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1, 401-412.
21. González Armas, J. C., Morello, C. S., Cranmer, L. D. & Spector, D. H. (1996). DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70, 7921-7928.
22. Gyulai, Z., Endresz, V., Burian, K. & 7 other authors (2000). Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181, 1537-1546.
23. Hansen, S. G., Strelow, L. I., Franchi, D. C., Anders, D. G. & Wong, S. W. (2003). Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 77, 6620-6636.
24. Huff, J. L., Eberle, R., Capitanio, J., Zhou, S.-S. & Barry, P. A. (2003). Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol 84, 83-92.
25. Jin, X., Demoitie, M. A., Donahoe, S. M. & 13 other authors (2000). High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J Infect Dis 181, 165-175.
26. Jonjić, S., del Val, M., Keil, G. M., Reddehase, M. J. & Koszinowski, U. H. (1988). A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 62, 1653-1658.
27. Kaur, A., Daniel, M. D., Hempel, D., Lee-Parritz, D., Hirsch, M. S. & Johnson, R. P. (1996). Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected macaques. J Virol 70, 7725-7733.
28. + T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J Virol 76, 3646-3658.
29. Kaur, A., Kassis, N., Hale, C. L. & 9 other authors (2003). Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 77, 5749-5758.
30. Kirchoff, V., Wong, S., St Jeor, S. & Pari, G. S. (2002). Generation of a life-expanded rhesus monkey fibroblast cell line for the growth of rhesus rhadinovirus (RRV). Arch Virol 147, 321-333.
31. Li, C.-R., Greenberg, P. D., Gilbert, M. J., Goodrich, J. M. & Riddell, S. R. (1994). Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83, 1971-1979.
32. Lockridge, K. M., Sequar, G., Zhou, S. S., Yue, Y., Mandell, C. P. & Barry, P. A. (1999). Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol 73, 9576-9583.
33. Loomis-Huff, J. E., Eberle, R., Lockridge, K. M., Rhodes, G. & Barry, P. A. (2001). Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine 19, 4865-4873.
34. + cytotoxic T-cell response in natural infection. Blood 104, 1075-1082.
35. McGregor, A., Liu, F. & Schleiss, M. R. (2004). Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). J Virol 78, 9872-9889.
36. McLaughlin-Taylor, E., Pande, H., Forman, S. J., Tanamachi, B., Li, C. R., Zaia, J. A., Greenberg, P. D. & Riddell, S. R. (1994). Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43, 103-110.
37. Morello, C. S., Cranmer, L. D. & Spector, D. H. (2000). Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 74, 3696-3708.
38. Morello, C. S., Ye, M., Hung, S., Kelley, L. A. & Spector, D. H. (2005). Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 79, 159-175.
39. Nakai, K. & Horton, P. (1999). PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 24, 34-36.
40. Nakai, K. & Kanehisa, M. (1992). A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 14, 897-911.
41. Nigro, G., Adler, S. P., La Torre, R. & Best, A. M. (2005). Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353, 1350-1362.
42. Ohlin, M., Plachter, B., Sundqvist, V. A., Steenbakkers, P. G. A., Middeldorp, J. M. & Borrebaeck, C. A. K. (1995). Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus. Clin Diagn Lab Immunol 2, 325-329.
43. Pande, N. T., Powers, C., Ahn, K. & Früh, K. (2005). Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11. J Virol 79, 5786-5798.
44. Penedo, M. C. T., Bontrop, R. E., Heijmans, C. M. C. & 7 other authors (2005). Microsatellite typing of the rhesus macaque MHC region. Immunogenetics 57, 198-209.
45. Reusser, P., Riddell, S. R., Meyers, J. D. & Greenberg, P. D. (1991). Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78, 1373-1380.
46. Reusser, P., Attenhofer, R., Hebart, H., Helg, C., Chapuis, B. & Einsele, H. (1997). Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 89, 3873-3879.
47. Reusser, P., Cathomas, G., Attenhofer, R., Tamm, M. & Thiel, G. (1999). Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 180, 247-253.
48. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. & Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241.
49. Sanchez, V., Angeletti, P. C., Engler, J. A. & Britt, W. J. (1998). Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol 72, 3321-3329.
50. Schleiss, M. R. & Heineman, T. C. (2005). Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4, 381-406.
51. Schleiss, M. R., McGregor, A., Jensen, N. J., Erdem, G. & Aktan, L. (1999). Molecular characterization of the guinea pig cytomegalovirus UL83 (pp65) protein homolog. Virus Genes 19, 205-221.
52. Schmolke, S., Drescher, P., Jahn, G. & Plachter, B. (1995). Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 69, 1071-1078.
53. Sequar, G., Britt, W. J., Lakeman, F. D., Lockridge, K. M., Tarara, R. P., Canfield, D. R., Zhou, S.-S., Gardner, M. B. & Barry, P. A. (2002). Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J Virol 76, 7661-7671.
54. Sindre, H., Rollag, H., Degré, M. & Hestdal, K. (2000). Human cytomegalovirus induced inhibition of hematopoietic cell line growth is initiated by events taking place before translation of viral gene products. Arch Virol 145, 99-111.
55. + T cells dominate the memory compartments of exposed subjects. J Exp Med 202, 673-685.
56. van Zanten, J., Harmsen, M. C., van der Giessen, M., van der Bij, W., Prop, J., de Leij, L. & The, T. H. (1995). Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins. Clin Diagn Lab Immunol 2, 214-218.
57. Vogel, P., Weigler, B. J., Kerr, H., Hendrickx, A. & Barry, P. A. (1994). Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques. Lab Anim Sci 44, 25-30.
58. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. & Riddell, S. R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333, 1038-1044.
59. Wang, Z., La Rosa, C., Mekhoubad, S. & 9 other authors (2004). Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104, 847-856.
60. Wills, M. R., Carmichael, A. J., Mynard, K., Jin, X., Weekes, M. P., Plachter, B. & Sissons, J. G. P. (1996). The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70, 7569-7579.
61. Yao, Z.-Q., Gallez-Hawkins, G., Lomeli, N. A., Li, X., Molinder, K. M., Diamond, D. J. & Zaia, J. A. (2001). Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine 19, 1628-1635.
62. Ye, M., Morello, C. S. & Spector, D. H. (2002). Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge. J Virol 76, 2100-2112.
63. Yue, Y., Zhou, S. S. & Barry, P. A. (2003). Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84, 3371-3379.